Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Somatrogon · Ngenla, MOD-4023

Recombinant protein · Agonist of growth hormone receptor (GHR) · developed by Pfizer Ireland Pharmaceuticals

Approved FDA, Jun 2023
PFE Developer
4 Registered trials

What is Somatrogon?

Somatrogon is a long-acting human growth hormone analog that binds the growth hormone receptor and activates STAT5b signaling, increasing serum IGF-1 and promoting linear growth. It is being studied in pediatric growth hormone deficiency and related conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ngenla, MOD-4023
Drug type
Recombinant protein
Targets
growth hormone receptor (GHR), STAT5b (binding partner it blocks), insulin-like growth factor 1 (IGF1) (biomarker)
Mechanism
Agonist of growth hormone receptor (GHR)
Pathways
GH receptor signal transduction, STAT5b signaling, IGF-1 production
Therapy area
Endocrine
Developer
Pfizer Ireland Pharmaceuticals (PFE)
Also in trials of
OPK
FDA status
Approved as Ngenla (June 27, 2023), BLA761184 · FDA label
UNII
6D848RA61B

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02968004 Phase 3 Pediatric Growth Hormone Deficiency Completed OPK
NCT03810664 Phase 1 Healthy Male Volunteers Completed OPK
NCT01060722 Phase 1 Healthy Completed OPK
NCT06587035 N/A Dwarfism, Pituitary Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dwarfism, PituitaryHealthyHealthy Male VolunteersPediatric Growth Hormone Deficiency

Other drugs acting on GHR

More from Pfizer Ireland Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Somatrogon

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.